LncRNA DSCAM-AS1 Promotes Colorectal Cancer Progression by Acting As a Molecular Sponge of MiR-384 to Modulate AKT3 Expression

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 May 27

PMID 32453706

Citations 14

Authors

Bo Li

Hai Sun

Jiayu Zhang

Affiliations

Soon will be listed here.

Abstract

Down Syndrome Cell Adhesion Molecule antisense1 (DSCAM-AS1), a novel long non-coding RNA (lncRNA), reportedly contributes to the development and progression of several cancers. There is a lack of information on its biological role and regulatory mechanism with respect to colorectal cancer (CRC). Here, we discovered that the expression of DSCAM-AS1 exhibited a significant upregulation in CRC tissues and cell lines in comparison with the corresponding control. Increased DSCAM-AS1 expression was associated with poor prognosis for those diagnosed with CRC. Loss-of function assay illustrated that knockdown of DSCAM-AS1 resulted in significant inhibition of cell proliferation, invasion and migration , and impaired tumor growth . MicroRNA-384(miR-384) was directly targeted by DSCAM-AS1 in CRC cells, and repression of DSCAM-AS1 inhibited the expression of AKT3, a known target of miR-384 in CRC. In addition, repression of miR-384 or overexpression of AKT3 could partially rescue the inhibitory effect of DSCAM-AS1 knockdown on CRC progression. In summary, DSCAM-AS1 exerted an oncogenic role in CRC by functioning as a competing endogenous RNA of miR-384 to bring about regulation of AKT3 expression. These results implied that DSCAM-AS1 might be a novel therapeutic target for patients suffering from CRC.

Citing Articles

N-methyladenosine-modified circ_0006168 promotes epithelial mesenchymal transition via miR-384/STAT3/Snail axis in esophageal squamous cell carcinoma.

Wu G, Hou Q, Liu Z, Pu Z, Wu L J Cancer. 2024; 15(15):4939-4954.

PMID: 39132166 PMC: 11310886. DOI: 10.7150/jca.97533.

MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB.

Sun Y, Wang J, Qiu M, Zhao J, Zou F, Meng M Cancer Biol Med. 2024; 21(11).

PMID: 38940672 PMC: 11667777. DOI: 10.20892/j.issn.2095-3941.2024.0146.

YY1-induced lncRNA00511 promotes melanoma progression via the miR-150-5p/ADAM19 axis.

Chen Y, Fu X, Guo H, Fu X, Shi K, Gao T Am J Cancer Res. 2024; 14(2):809-831.

PMID: 38455406 PMC: 10915319.

The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers.

Yang C, Hardy P Cells. 2023; 12(22).

PMID: 37998329 PMC: 10670075. DOI: 10.3390/cells12222594.

In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer.

Lee C, Lee A, Wei P, Liu Y, Chang Y, Huang C Sci Rep. 2023; 13(1):4366.

PMID: 36927770 PMC: 10020571. DOI: 10.1038/s41598-023-31331-2.

References

Ulitsky I, Bartel D . lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46. PMC: 3924787. DOI: 10.1016/j.cell.2013.06.020. View

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

Han D, Wang M, Ma N, Xu Y, Jiang Y, Gao X . Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett. 2015; 361(1):13-21. DOI: 10.1016/j.canlet.2015.03.002. View

Mercer T, Dinger M, Mattick J . Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10(3):155-9. DOI: 10.1038/nrg2521. View

Hong Z, Fu W, Wang Q, Zeng Y, Qi L . MicroRNA-384 is lowly expressed in human prostate cancer cells and has anti-tumor functions by acting on HOXB7. Biomed Pharmacother. 2019; 114:108822. DOI: 10.1016/j.biopha.2019.108822. View

Wang Y, Chen Y, Liu S, Ye Y, Jiao H, Wang S . MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget. 2016; 7(51):84826-84838. PMC: 5356701. DOI: 10.18632/oncotarget.12704. View

Chen L, Dzakah E, Shan G . Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018; 418:119-124. DOI: 10.1016/j.canlet.2018.01.042. View

Ji D, Hu G, Zhang X, Yu T, Yang J . Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma via sponging miR-338-3p. Am J Transl Res. 2019; 11(7):4290-4302. PMC: 6684899. View

Di Leva G, Garofalo M, Croce C . MicroRNAs in cancer. Annu Rev Pathol. 2013; 9:287-314. PMC: 4009396. DOI: 10.1146/annurev-pathol-012513-104715. View

10.

Brenner H, Chen C . The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br J Cancer. 2018; 119(7):785-792. PMC: 6189126. DOI: 10.1038/s41416-018-0264-x. View

11.

Li B, Xie Z, Li Z, Chen S, Li B . MicroRNA-613 targets FMNL2 and suppresses progression of colorectal cancer. Am J Transl Res. 2017; 8(12):5475-5484. PMC: 5209498. View

12.

Yang Y, Junjie P, Sanjun C, Ma Y . Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. J Cancer. 2017; 8(16):3212-3225. PMC: 5665037. DOI: 10.7150/jca.19794. View

13.

Liao J, Xie N . Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019; 23(3):1087-1092. DOI: 10.26355/eurrev_201902_16998. View

14.

Liang W, Li N, Yuan Z, Qian X, Wang Z . DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Mol Carcinog. 2018; 58(4):461-473. DOI: 10.1002/mc.22941. View

15.

Niknafs Y, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K . The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016; 7:12791. PMC: 5052669. DOI: 10.1038/ncomms12791. View

16.

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

17.

Li Y, Hao J, Jiang Y, Liu Y, Zhang S . Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4. Eur Rev Med Pharmacol Sci. 2019; 23(10):4143-4148. DOI: 10.26355/eurrev_201905_17916. View

18.

Fan N, Zhang J, Cheng C, Zhang X, Feng J, Kong R . MicroRNA-384 represses the growth and invasion of non-small-cell lung cancer by targeting astrocyte elevated gene-1/Wnt signaling. Biomed Pharmacother. 2017; 95:1331-1337. DOI: 10.1016/j.biopha.2017.08.143. View

19.

Ma Y, Bu D, Long J, Chai W, Dong J . LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. J Cell Physiol. 2018; 234(3):2880-2894. DOI: 10.1002/jcp.27105. View

20.

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View